APA (7th ed.) Citation

De la Garza-Salazar, F. (2026). Intentional CYP3A4 inhibition in venetoclax-based AML therapy: From incidental observation to validated clinical strategy. Leukemia & Lymphoma, 1. https://doi.org/10.1080/10428194.2026.2685236

Chicago Style (17th ed.) Citation

De la Garza-Salazar, Fernando. "Intentional CYP3A4 Inhibition in Venetoclax-based AML Therapy: From Incidental Observation to Validated Clinical Strategy." Leukemia & Lymphoma 2026: 1. https://doi.org/10.1080/10428194.2026.2685236.

MLA (9th ed.) Citation

De la Garza-Salazar, Fernando. "Intentional CYP3A4 Inhibition in Venetoclax-based AML Therapy: From Incidental Observation to Validated Clinical Strategy." Leukemia & Lymphoma, 2026, p. 1, https://doi.org/10.1080/10428194.2026.2685236.